Some safety aspects of a new russian pegylated interferon-A medication “ALGERON” (phase 1 clinical trial)

Cover Page
  • Authors: Tukach AI1, Fitilev SB1, Shkrebniova II1, Vozzhaev AV1, Yakushev VA1, Ivanov RA2, Lin’kova Y.N2, Chernovskaya TV2
  • Affiliations:
    1. Peoples’ Friendship University of Russia
    2. «Biocad», Research and Development
  • Issue: No 2 (2014)
  • Pages: 114-118
  • Section: Articles
  • URL: http://journals.rudn.ru/medicine/article/view/2867
  • Cite item

Abstract


Treatment of hepatitis C is one of the most acute international healthcare problems. High standard in management of patients with HCV virus is combined therapy with pegylated interferon-a plus ribavirin. A necessity to develop new medications and to improve current treatment regiments is determined by high social and economic significance of this disease. Safety and tolerance assessment in healthy volunteers, definition of maximum tolerated dose are conducted in first phase clinical trial of original, Russian medication - pegylated interferon-a, named Algeron (INN - Cepeginterferon alfa-2b). Step by step dose escalation of Algeron in groups of several healthy volunteers was applied in this trial. Results of this trial demonstrated, that safety profile of Algeron has no significant differences with safety profiles of analogical pegylated interferon-a medications. Thus Algeron can be recommended for the second phase clinical trials.

About the authors

A I Tukach

Peoples’ Friendship University of Russia

Email: fitilevsb@yandex.ru
Department of general and clinic pharmacology

S B Fitilev

Peoples’ Friendship University of Russia

Email: fitilevsb@yandex.ru
Department of general and clinic pharmacology

I I Shkrebniova

Peoples’ Friendship University of Russia

Email: fitilevsb@yandex.ru
Department of general and clinic pharmacology

A V Vozzhaev

Peoples’ Friendship University of Russia

Email: fitilevsb@yandex.ru
Department of general and clinic pharmacology

V A Yakushev

Peoples’ Friendship University of Russia

Email: fitilevsb@yandex.ru
Department of general and clinic pharmacology

R A Ivanov

«Biocad», Research and Development

Email: fitilevsb@yandex.ru

Yu N Lin’kova

«Biocad», Research and Development

Email: fitilevsb@yandex.ru

T V Chernovskaya

«Biocad», Research and Development

Email: fitilevsb@yandex.ru

References

Statistics

Views

Abstract - 105

PDF (Russian) - 48

Cited-By



Copyright (c) 2014 Тукач А.И., Фитилев С.Б., Шкребнева И.И., Возжаев А.В., Якушев В.А., Иванов Р.А., Линькова Ю.Н., Черновская Т.В.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies